Cognitive changes associated with central nervous system malignancies and treatment.

Objectives: To review the cognitive changes associated with infiltrative, malignant brain tumors and treatments for brain tumors.

Data Source: Review of journal articles and textbooks.

Conclusion: Improvements in surgical, radiation, and medical therapies for central nervous system malignancies have resulted in increased patient survival.

It's not your "run of the mill" meningioma: characteristics differentiating low-grade from high-grade meningeal tumors.

Approximately 30% of primary brain tumors are meningiomas; 90% of these are benign. The remaining 10% have aggressive pathological features and significantly higher recurrence rates. Treatments include surgery, radiation therapy, and other medical therapies.

Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience.

Background: Gliadel (polifeprosan 20 with carmustine [BCNU] implant) is commonly used for local delivery of BCNU to high-grade gliomas after resection and is associated with increased survival. Various complications of Gliadel wafers have been reported but not consistently reproduced. We set out to characterize Gliadel-associated morbidity in our 10-year experience with Gliadel wafers for treatment of malignant glioma.